Adjunct in obesity (in conjunction with dietary measures
and increased physical activity in individuals with a
body mass index (BMI) of 30 kg/m2 or more or in
individuals with a BMI of 27 kg/m2 or more in the
presence of one or more weight related co-morbidity)
▶BY MOUTH
▶Adult 18–75 years: Initially 1 tablet daily for 7 days, then
increased to 1 tablet twice daily for 7 days, then
increased to 3 tablets daily in divided doses for 7 days,
two tablets to be taken in the morning, and one tablet
to be taken in the evening, then maintenance 2 tablets
twice daily, review treatment after 16 weeks and then
annually
DOSE EQUIVALENCE AND CONVERSION
▶Each tablet contains 8 mg naltrexone with 90 mg
bupropion.
PDF page 120
Uncontrolled hypertension
PDF page 121
History of mania. hypertension
PDF page 121
Prescribers
should consult the Mysimba ® Physician Prescribing
Checklist provided by the manufacturer, before initiation
of treatment.
PDF page 121
NICE decisions
▶Naltrexone–bupropion for managing overweight and obesity
(December 2017) NICE TA494
Naltrexone–bupropion is not recommended within its
marketing authorisation for managing overweight and
obesity in adults alongside a reduced-calorie diet and
increased physical activity.
Patients whose treatment was started within the NHS
before this guidance was published should have the option
to continue treatment, without change to their funding
arrangements, until they and their NHS clinician consider
it appropriate to stop.
www.nice.org.uk/guidance/ta494
PDF page 121
